About Giten

Giten is currently the Community and Policy Project Manager at amfAR’s TREAT Asia program in Bangkok, Thailand.  He has been working on improving hepatitis C treatment access and advocating for price reductions in South and South East Asia in partnership with regional and national community networks.  Giten also has been providing training to national PLHIV and PWID networks on hepatitis C treatment, access issues and direct-acting antivirals and their use with antiretroviral therapy. His involvement in regional advocacy for hepatitis C treatment access has included efforts to engage with global stakeholders, including innovator and generic pharmaceutical companies to address price- and non-price barriers. He was also profiled as a Change Maker for hepatitis C by the Economist Intelligence Unit in 2016.

This speaker will be presenting at the following session(s)

  • Access to hepatitis medicines

    Golden Hall

    Day: 2 November

    Time: 11:15

    This panel session examines the key barriers and current strategies to scale up access to hepatitis treatment.

    Chair: Dr. Jackson Amone, Ministry of Health, Uganda and Ricardo Baptista Leite, Member of the Portuguese Parliament and Católica University of Portugal


    • Generic DAAs; where they are and for how much.
    • Giten Khwairakpam, amfAR
    • What price for what drug: is there a science to it?
    • Dr. Andrew Hill, Liverpool University, UK
    • Options for treatment access in countries with and without access to generics and role of different actors.
    • Dr. Yvan Hutin, World Health Organization


    • To review different approaches to overcoming access barriers and the progress made.